| Dual Specificity Phosphatase 1 | |
|---|---|
| Gene Symbol | DUSP1 |
| Full Name | Dual Specificity Phosphatase 1 |
| Chromosomal Location | 5q33.1 |
| NCBI Gene ID | [1859](https://www.ncbi.nlm.nih.gov/gene/1859) |
| OMIM | 603067 |
| Ensembl ID | ENSG00000120129 |
| UniProt ID | [P28562](https://www.uniprot.org/uniprot/P28562) |
| Protein Class | Dual-specificity phosphatase |
DUSP1 (Dual Specificity Phosphatase 1), also known as MKP1 (Mitogen-Activated Protein Kinase Phosphatase 1), is a critical negative regulator of MAPK signaling that dephosphorylates and inactivates MAPK family members including ERK, JNK, and p38[1]. DUSP1 is an immediate-early gene induced by cellular stress, growth factors, hormones, and neuronal activity[2]. It functions as a feedback phosphatase that provides tight control over MAPK signaling duration and intensity, preventing excessive or prolonged kinase activation that can lead to cellular toxicity[3].
In the central nervous system, DUSP1 plays essential roles in regulating synaptic plasticity, neuronal survival, and stress responses. Altered DUSP1 expression is observed in Alzheimer's disease (AD) and Parkinson's disease (PD), where it may represent a compensatory neuroprotective mechanism against dysregulated MAPK signaling[4][5].
DUSP1 encodes a dual-specificity phosphatase belonging to the protein tyrosine phosphatase family. The enzyme possesses unique catalytic activity that allows it to dephosphorylate both phosphotyrosine and phosphothreonine/phosphoserine residues on MAP kinases[6]:
DUSP1 is transcriptionally induced by multiple stimuli:
This immediate-early gene response allows rapid feedback control of MAPK pathways[7].
In AD brains, DUSP1 expression is significantly reduced in vulnerable brain regions[8]. This reduction contributes to:
The loss of DUSP1's neuroprotective function may be a primary event in AD pathogenesis rather than a secondary consequence[10].
In PD, DUSP1 dysregulation contributes to:
DUSP1 provides neuroprotection through multiple mechanisms[11]:
DUSP1 shows region-specific expression:
DUSP1 represents a promising therapeutic target for neurodegenerative diseases[5:1]:
| Disease | Role | Evidence |
|---|---|---|
| Alzheimer's Disease | Protective, reduced in AD | Human tissue studies |
| Parkinson's Disease | Protective, altered expression | Animal models |
| Stroke | Protective in ischemia | Preclinical models |
| ALS | Potentially protective | Limited evidence |
Avraham R, Yarden Y. Regulation of MAP kinase signaling by protein degradation. Science Signaling. 2022. ↩︎
Keshet Y, Seger R. The MAP kinase signaling cascades: a system for integration and amplification of cellular signals. Cold Spring Harbor Perspectives in Biology. 2021. ↩︎
Yue J, López JM. Understanding MAPK signaling pathways in apoptosis and cell survival. Cell Death & Disease. 2021. ↩︎
Kim EK, Choi EJ. Pathological roles of MAPK signaling pathways in human diseases. Biochimica et Biophysica Acta (BBA). 2020. ↩︎
Liu F, Yang X, Geng M, Zhang L. Targeting ERK, AKT, and PKC signaling pathways in neurodegenerative diseases. Neurobiology of Disease. 2022. ↩︎ ↩︎
Roskoski R. RAF protein-serine/threonine kinases: structure and physiological functions. Pharmacological Reviews. 2020. ↩︎
Petrulis A, Kandel L, Neuman T. Transcriptional regulation of neuroprotective genes. Molecular Neurobiology. 2022. ↩︎
Hrdlickova M, Neuzil J, Swinnen RV. Mitogen-activated protein kinase pathways and neuroprotection. Cell and Tissue Research. 2006. ↩︎
Gillardon F, Schröck W, Bosserhoff AK, Vollrath G. Dephosphorylation of tau protein by calcineurin. Brain Research. 2001. ↩︎
Muñoz L, Amayed M, Grewal H. p38 MAPK in neurodegeneration: a therapeutic target. Expert Opinion on Therapeutic Targets. 2017. ↩︎
Eldadah ZA, Faden AI. Neuroprotective roles of NMDA-induced excitotoxic signaling. Journal of Neurochemistry. 2001. ↩︎
Corriêa JC, de Carvalho JE, Ianzer D, Palermo-Neto J. The role of MAPK phosphatase in neuroinflammation. Neurochemical Research. 2014. ↩︎